Brookline Capital Management Estimates C4 Therapeutics FY2030 Earnings

C4 Therapeutics, Inc. (NASDAQ:CCCC) – Investment analysts at Brookline Capital Management issued their FY2030 earnings estimates for shares of C4 Therapeutics in a report released on Monday, January 5th. Brookline Capital Management analyst L. Cann expects that the company will post earnings of $40.97 per share for the year. The consensus estimate for C4 Therapeutics’ current full-year earnings is ($1.52) per share.

C4 Therapeutics (NASDAQ:CCCC) last announced its earnings results on Thursday, November 6th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.03. C4 Therapeutics had a negative net margin of 395.51% and a negative return on equity of 64.40%. The firm had revenue of $11.23 million for the quarter, compared to analyst estimates of $6.28 million.

Several other research firms have also issued reports on CCCC. Stephens reissued an “overweight” rating and set a $6.00 target price on shares of C4 Therapeutics in a report on Monday, September 22nd. Wells Fargo & Company raised their target price on shares of C4 Therapeutics from $5.00 to $10.00 and gave the company an “overweight” rating in a report on Tuesday, September 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of C4 Therapeutics in a research report on Wednesday, October 8th. Barclays reduced their price target on shares of C4 Therapeutics from $10.00 to $5.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 17th. Finally, TD Cowen assumed coverage on shares of C4 Therapeutics in a research report on Tuesday, December 2nd. They set a “buy” rating for the company. Six analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $7.25.

C4 Therapeutics Price Performance

Shares of NASDAQ:CCCC opened at $2.03 on Tuesday. The business’s 50 day simple moving average is $2.36 and its 200 day simple moving average is $2.33. C4 Therapeutics has a 1 year low of $1.09 and a 1 year high of $4.26. The company has a market capitalization of $196.73 million, a P/E ratio of -1.22 and a beta of 2.93.

Institutional Trading of C4 Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd bought a new position in shares of C4 Therapeutics in the 3rd quarter valued at $43,000. Jacobs Levy Equity Management Inc. increased its holdings in C4 Therapeutics by 13.9% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 503,145 shares of the company’s stock worth $1,117,000 after purchasing an additional 61,410 shares in the last quarter. Voleon Capital Management LP acquired a new stake in shares of C4 Therapeutics during the third quarter valued at about $63,000. Qube Research & Technologies Ltd bought a new stake in shares of C4 Therapeutics during the third quarter worth about $257,000. Finally, Bank of America Corp DE grew its holdings in shares of C4 Therapeutics by 2.2% during the third quarter. Bank of America Corp DE now owns 2,053,162 shares of the company’s stock worth $4,558,000 after purchasing an additional 45,158 shares during the last quarter. Institutional investors own 78.81% of the company’s stock.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degraders. Utilizing its proprietary Controlled Inducible Degradation (CiD) platform, the company seeks to eliminate disease-causing proteins by harnessing the body’s natural protein disposal machinery. This approach aims to address a wide range of oncology and immuno-oncology indications by targeting proteins that have historically been difficult to inhibit with traditional small molecules or antibodies.

The company’s pipeline includes multiple small-molecule degrader candidates advancing through preclinical and clinical stages.